Sarizotan (BioDeep_00000838006)
代谢物信息卡片
化学式: C22H21FN2O (348.1637828)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC2=CC=CC=C2OC1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F
InChI: InChI=1S/C22H21FN2O/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2/t21-/m1/s1
描述信息
C26170 - Protective Agent > C1509 - Neuroprotective Agent
Sarizotan (EMD 128130) is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively[1].
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 6918388
- DrugBank: DB06454
- ChEMBL: CHEMBL220808
- CAS: 351862-32-3
- medchemexpress: HY-100820
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wojciech Danysz, Gunnar Flik, Andrew McCreary, Carsten Tober, Wilfried Dimpfel, Jean C Bizot, Richard Kostrzewa, Russell W Brown, Claudia C Jatzke, Sergio Greco, Ann-Kristin Jenssen, Christopher G Parsons. Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.
Journal of neural transmission (Vienna, Austria : 1996).
2015 Sep; 122(9):1221-38. doi:
10.1007/s00702-015-1392-6. [PMID: 25796190] - Dieter Gallemann, Elmar Wimmer, Constance C Höfer, Achim Freisleben, Markus Fluck, Bernhard Ladstetter, Hugues Dolgos. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Jun; 38(6):905-16. doi:
10.1124/dmd.109.029835. [PMID: 20219851] - Laurent Grégoire, Pershia Samadi, Julie Graham, Paul J Bédard, Gerd D Bartoszyk, Thérèse Di Paolo. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Parkinsonism & related disorders.
2009 Jul; 15(6):445-52. doi:
10.1016/j.parkreldis.2008.11.001. [PMID: 19196540] - C Marin, E Aguilar, M C Rodríguez-Oroz, G D Bartoszyk, J A Obeso. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Psychopharmacology.
2009 Jun; 204(2):241-50. doi:
10.1007/s00213-008-1452-9. [PMID: 19159919] - S Krösser, J Tillner, M Fluck, W Ungethüm, P Wolna, A Kovar. Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects.
International journal of clinical pharmacology and therapeutics.
2007 May; 45(5):271-80. doi:
10.5414/cpp45271. [PMID: 17542349] - Sonja Krösser, Roland Neugebauer, Hugues Dolgos, Markus Fluck, Karl-Ludwig Rost, Andreas Kovar. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
European journal of clinical pharmacology.
2006 Apr; 62(4):277-84. doi:
10.1007/s00228-006-0101-7. [PMID: 16525816]